title: T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).
abstract: Complement receptor 2 (CR2, CD21), the receptor for both the C3d,g portion of human complement component C3 and the Epstein-Barr virus, has been recently described on peripheral T cells. By using dual stain flow cytometric analysis, we have also observed that a peripheral T lymphocyte subpopulation of normal healthy donors bears CR2 in a range varying from 1.1 to 23.2% (mean 12.6%) of total CD3+ cells. T lymphocytes from nine patients with inactive SLE expressed CR2 in a similar range. Three patients with active SLE were also studied. One of them, having neuropathy and glomerulonephritis, displayed an expansion of the CR2 T cell subpopulation which reached as much as 89% of total CD3+ cells. To examine potential functional roles of T cell CR2, cells from a Jurkat-derived CR2 expressing T cell line were found to bind in vitro to human CR2-, complement-coated K562 cell targets in a CR2- and complement-dependent fashion. Based on these studies, we hypothesize that CR2 might act to increase adherence of T cells to nucleated target cells bearing C3d,g, a function which may be relevant to cytotoxicity or other T cell activities requiring cell-cell interaction.
authors.affiliation: Howard Hughes Medical Institute Laboratories, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110.
authors.forename: E
authors.initials: E
authors.lastname: Levy
authors.forename: J
authors.initials: J
authors.lastname: Ambrus
authors.forename: L
authors.initials: L
authors.lastname: Kahl
authors.forename: H
authors.initials: H
authors.lastname: Molina
authors.forename: K
authors.initials: K
authors.lastname: Tung
authors.forename: V M
authors.initials: VM
authors.lastname: Holers
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D002448:Cell Adhesion; D003176:Complement C3 / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D008180:Lupus Erythematosus, Systemic / Q000503:physiopathology*; D008213:Lymphocyte Activation; D017464:Receptors, Complement 3d / Q000378:metabolism*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000502:physiology*; D014407:Tumor Cells, Cultured
chemical_list: D003176:Complement C3; D017464:Receptors, Complement 3d